<DOC>
	<DOCNO>NCT01808521</DOCNO>
	<brief_summary>In study , investigator want determine N-acetylcysteine ( NAC ) , give intravenously , decrease complication patient Thrombotic Thrombocytopenia Purpura ( TTP ) receive treatment therapeutic plasma exchange ( TPE ) . The investigator want determine , anti-oxidant activity , NAC additional efficacy TTP improve cleavage patient ' VWF ADAMTS13 , prevent propagation platelet/VWF string . This manifest rapid improvement patient 's platelet count , decrease number day require TPE , decrease microvascular thrombotic complication . The investigator additionally : 1 ) Assess safety NAC evaluate subject adverse event significant adverse event 2 ) Determine effect TTP measure clinical research laboratory value 3 ) Determine drug effect measure clinical research laboratory value .</brief_summary>
	<brief_title>A Pilot Study N-acetylcysteine Thrombotic Thrombocytopenia Purpura</brief_title>
	<detailed_description>Thrombotic thrombocytopenic purpura ( TTP ) rare hemostatic disorder life threaten consequence secondary microvascular thrombosis . While use therapeutic plasma exchange ( TPE ) greatly improve survival , end organ damage , resistance therapy , relapse occur many patient . Ultra-large von Willebrand factor multimers ( ULVWF ) pathogenic TTP . The investigator find N-acetylcysteine ( NAC ) cleave ULVWF vitro vivo ADAMTS13 deficient mouse increase risk TTP . NAC well tolerate human intravenous dos use treatment acetaminophen overdose . This dosage correlate produce effect murine study note , thus attractive treatment patient TTP . By cleave VWF prevent propagation platelet/VWF string , investigator hypothesize NAC treatment decrease complication patient TTP receive treatment TPE . This manifest rapid improvement platelet count , decrease number day require plasma exchange , decrease microvascular thrombotic complication . To prepare large trial investigator propose pilot study 3 patient suspect TTP University Washington ( UW ) Medical Center . The study approve UW IRB prior study initiation . Patients consent study receive daily NAC infusion begin first TPE , dose use acetaminophen overdose . Blood sample collect laboratory assay determine optimal timing sample collection large multicenter trial , pilot data collection form . The investigator also evaluate safety patient tolerability .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura , Thrombotic Thrombocytopenic</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>1 . Age &gt; = 18 year age 2 . Diagnosis suspect TTP ( lab evidence hemolysis , platelet count &lt; 120,000 , schistocytes peripheral smear ) 3 . Plans initiate therapeutic plasma exchange ( TPE ) , 3rd TPE 4 . Normal baseline prothrombin time ( PT ) activate partial thromboplastin time ( aPTT ) 5 . Anticipated TPE &gt; 5 day 1 . Asthma 2 . Life expectancy &lt; 1 week 3 . Liver function test abnormal ( ALT , direct bilirubin &gt; three time upper normal limit ) 4 . Known underlie bleed disorder 5 . Pregnancy nurse 6 . Known allergy NAC 7 . Phosphodiesterase Type 5 inhibitor , nitroglycerin , carbamazepine current use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Purpura , Thrombotic Thrombocytopenic</keyword>
	<keyword>TTP</keyword>
</DOC>